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COST AND RESOURCE UTILIZATION OF RESPIRATORY SYNCYTIAL 
VIRUS (RSV) OR WINTER UNSPECIFIED BRONCHIOLITIS OR 
PNEUMONIA (UBP) HOSPITALIZATIONS DURING THE FIRST YEAR 
OF LIFE AMONG LATE PRETERM AND FULL-TERM INFANTS
Forbes ML1, Hall CB2, Jackson A3, Masaquel A4, Mahadevia PJ4
1Akron Children’s Hospital, Akron, OH, USA, 2University of Rochester Medical School, 
Rochester, NY, USA, 3Milliman, Inc, Indianapolis, IN, USA, 4MedImmune, Inc., Gaithersburg, MD, 
USA
OBJECTIVES: To estimate the total costs and resource utilization of RSV or UBP 
hospitalizations among late preterm vs. full-term infants during their ﬁ rst year. 
METHODS: This retrospective cohort study examined the MarketScan Commercial
Claims and Encounters database from January 2003 to June 2007. First hospital 
admission with ICD-9 CM diagnosis codes for RSV (466.11, 480.1, 079.6) or UBP
(466.19, 485, 486) during November-March were identiﬁ ed among infants 1 year 
old. Cohorts included 1) early preterm infants 33 weeks gestational age (wGA); and 
infants with chronic lung disease; 2) late preterm infants 33–36 wGA, and 3) full-term 
infants q37 wGA. The average costs of RSV and UBP hospitalizations, use of health 
care resources, and patient demographics were examined. Descriptive analyses
included a Wilcoxon test for continuous variables and a two-sided test t-test for cate-
gorical variables (alpha  0.05). RESULTS: Early, late, and full-term infants had 46, 
149 and 1983 RSV hospitalizations, respectively. Across cohorts, infants were an 
average of 3–4 months of age and mostly males. RSV hospitalization costs were sig-
niﬁ cantly higher among early preterm ($13,876, SD  $14,453) (p  0.01) and late
preterm infants ($18,403, SD  $31,792) (p  0.001) compared to full-term infants
($9,014, SD  $26,769). Late preterm infants had a signiﬁ cantly higher mean length 
of hospital stay (4.9 vs. 3.2 days), intensive care unit admission (22% vs. 9.6%), and
comorbid conditions (10% vs. 1.3%) compared to full-term infants (each p  0.001). 
Early and late preterm compared to full-term infants also had higher UBP hospitaliza-
tion costs and resource use. CONCLUSIONS: Since about three-fourths of all prema-
turely born infants are late preterm infants, the signiﬁ cantly higher RSV-associated 
costs of late preterm infants compared to full-term infants impose a major health care 
burden. Analysis of health care costs at birth and through the ﬁ rst year of life may 
help evaluate strategies to prevent RSV among late preterm infants.
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INCREMENTAL ASTHMA-RELATED EXPENDITURES ASSOCIATED 
WITH HIGH UTILIZATION OF SHORT ACTING b-AGONISTS AMONG 
A COMMERCIALLY INSURED ASTHMATIC POPULATION IN THE U.S.
Kamble S1, Blanchette CM2, Silver H2, Petersen H2, Meddis D3, Gutierrez B3
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OBJECTIVES: To determine the incremental direct asthma–related expenditures asso-
ciated with six or more SABA canisters per year in a commercially insured asthmatic
population in the US. METHODS: A retrospective cohort study was conducted for 
asthmatic patients (aged 6–56 years; n  93,604) with two-year continuous enrollment
in the PHARMetrics database between July 2003-June 2007, 1 hospitalization/emer-
gency department (ED) or 2 outpatient claims with an International Classiﬁ cation of 
Diseases, 9th Revision, Clinical Modiﬁ cation (ICD-9-CM) code 493.XX and 1 
asthma medication claim in each of the two years of observation. Patients with COPD 
and diseases associated with chronic oral steroid use were excluded. SABA utilization
was converted to canister-count/year and categorized into 0–5 and 6. Generalized 
linear model(GLM) with log-link and a gamma variance function was used to estimate 
the incremental total expenditures, medical and pharmaceutical expenditures associ-
ated with use of 6 canisters per year. Covariates included age, sex, region, post-index 
asthma controller use, several ﬁ rst-year severity measures and comorbidities. Age
stratiﬁ ed analysis (adults: age 18–56 yrs; pediatrics: age 6–17 yrs) using the GLM
technique was also conducted to estimate the incremental expenditures. RESULTS:
80,353 patients (85.7%) used 0–5 canisters per year whereas 13,251 patients (14.1%)
used 6 canisters per year. Patients with asthma who used 6 SABA canisters per 
year had 41.2% higher total asthma-related expenditures (95% CI: 1.39 to 1.43), 
33.1% higher asthma-related medical expenditures (95% CI: 1.29 to 1.37), and 
39.1% higher asthma-related pharmaceutical expenditures (95% CI: 1.37 to 1.41) 
than those who used 0–5 SABA canisters per year after controlling for covariates. 
Results were similar for both adult and pediatric asthma populations. CONCLU-
SIONS: The use of six or more SABA canisters per year is associated with increased 
asthma related expenditures, suggesting a need for re-examining asthma management
in such high-risk patients with asthma.
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THE FINANCIAL IMPACT OF COMPUTER SYSTEMS–BASED 
APPROACHES TO REDUCING REPEAT DRUG EXPOSURE IN PATIENTS 
WITH KNOWN DRUG ALLERGIES
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OBJECTIVES: There is increasing cognition internationally on reducing the high
disease burden resulting from errors in medication use. Repeat exposure to drugs to
which patients have a known allergy has been classiﬁ ed as a repeatedly identiﬁ ed
error. These repeat reactions should therefore be preventable. The objective of this 
study was to implement computer systems to reducing the risk of reexposure and to 
evaluate the ﬁ nancial impact of these approaches in Taipei Medical University-Shuang
Ho Hospital. METHODS: We use computerized physician order entry systems incor-
porating hazard messages that alert or block health care professionals to patients’ 
allergies. The computer systems can store patient allergy information centrally and
ensure it is up-to-date and readily available in different settings. Besides the computer
systems can automatically transfer every suspected drug into the Anatomical Thera-
peutic Chemical codes that will be recognized by the system more effectively. This in 
turn leads to completely block repeat drug exposure in patients with known drug
allergies. The determination of ﬁ nancial impact was expressed by cost avoidance per 
year in Taiwan. RESULTS: The data from our studies suggest that about 10% of 
medication errors are due to patients receiving a medication to which they were 
already known to be allergic. This can translates into between 6,900 and 13,800 epi-
sodes per year in Taiwan. The estimated cost avoidance will be as high as NT 34.5 
million to 69 million per year (based on the assumption that cost of allergy treatment
is about NT 5,000) through this CPOE in combination with allergy warning and
blocking system. CONCLUSIONS: There is an increasing body of epidemiologic work 
indicating that adverse drug reactions caused by known drug allergies are relatively 
common and potentially preventable. The implementation of computer systems-based 
approaches has the potential to improve medication safety and reduce the expenditure 
of medical expenses.
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OBJECTIVES: To determine the cost-effectiveness of the grass allergen immunother-
apy tablet (AIT), Grazax (ALK-Abelló A/S) for the treatment of grass pollen induced
rhinoconjunctivitis in children either with or without co-existing asthma. The analysis
compares treatment using Grazax in combination with symptomatic medications, to 
using symptomatic medications alone in terms of costs and health outcomes. 
METHODS: The model uses a decision tree structure to evaluate two grass pollen 
induced rhinoconjunctivitis treatments for a cohort of 1000 hypothetical children. 
The analysis is performed from the perspective of the payer, including only direct costs 
in the base case. Treatment is modelled in terms of the management of symptoms,
reduction in resource use and averting the development of allergic asthma. The evalu-
ation is UK-based and models both short- and long-term effects. Several data 
inputs, such as resource use and probabilities, are drawn from the paediatric GT-12 
clinical trial and the Preventive Allergy Treatment (PAT) study. Cost data are sourced
from established published sources and utility values are derived using GT-12 trial 
data and a published study. RESULTS: Treatment with Grazax in combination 
with symptomatic medications compared to treatment with symptomatic medications
alone generates a (discounted) incremental cost per QALY gained of 10,007GBP
($14,578, €11,034), for the base case time horizon of nine years. The QALY gains 
are a result of increased quality of life related to effective symptom management. The 
sensitivity analysis carried out around key parameters (e.g. unit costs, medication
costs, probabilities, utilities) shows that the results estimated by the model remain 
robust. CONCLUSIONS: Grazax has been shown to improve patient outcomes,
at an increased cost. The resulting incremental cost per QALY falls below commonly
accepted willingness to pay thresholds. Therefore, Grazax is a cost-effective option 
for the treatment of grass pollen induced rhinoconjunctivitis in the UK paediatric 
population.
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OBJECTIVES: To estimate the number and cost of asthma-related productivity loss
days due to absenteeism and presenteeism in Alberta in 2005. METHODS: Using data 
from the 2005 Canadian Community Health Survey, this study focused on people of 
working age (18–64 years). Total asthma-related disability days, including in-bed days 
and activity-restricted days, were estimated by multiplying the difference in the means 
of total disability days between asthmatics and non-asthmatics adjusted for socio-
demographic characteristics and other health conditions by a multivariate linear 
regression, with the number of asthmatics in the population. Number of productivity
loss days was a sum between the number of in-bed days (absenteeism) and the number 
of activity-restricted days multiplied by a reduction in functional level (presenteeism), 
adjusted for 5 working days per week. Other data from Alberta or Canadian published
literature, such as a reduction in functional level of 20%–30%, a labour participation
rate of 73%, and an average wage of $158 per day in 2005, were also used for analy-
ses. RESULTS: The prevalence of asthma was estimated at 8.5% among approxi-
mately 2.1 million people of working age in Alberta in 2005. The difference in the
means of total disability days between asthmatics and non-asthmatics was 0.487 
(95%CI: 0.286–0.666) in a period of two weeks or 12.7 (7.5–17.9) in one year. With 
the reduction in functional level of 20%–30%, the number of asthma-related produc-
tivity loss days was estimated from 442 (259–624) to 533 (313–753) thousand,
respectively. The corresponding cost was from $70 ($41–$99) to $84 ($49–$119)
million. Of these, the presenteeism accounted for 42% to 52%. CONCLUSIONS: An 
improvement in controlling asthma could have a signiﬁ cant economic impact in 
Alberta. Presenteeism plays an important role in asthma-related productivity losses
and therefore employers should not only pay attention to absenteeism, but also to 
presenteeism, to minimize productivity loss.
